| 1.15 -0.05 (-4.17%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.72 |
1-year : | 1.97 |
| Resists | First : | 1.47 |
Second : | 1.69 |
| Pivot price | 1.31 |
|||
| Supports | First : | 1.13 |
Second : | 0.94 |
| MAs | MA(5) : | 1.25 |
MA(20) : | 1.32 |
| MA(100) : | 1.1  |
MA(250) : | 0.93 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.9 |
D(3) : | 19.7 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 1.78 | Low : | 0.57 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PASG ] has closed above bottom band by 2.8%. Bollinger Bands are 35.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.28 - 1.29 | 1.29 - 1.3 |
| Low: | 1.12 - 1.13 | 1.13 - 1.14 |
| Close: | 1.19 - 1.2 | 1.2 - 1.21 |
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Fri, 19 Apr 2024
Passage Bio (NASDAQ:PASG) Stock Price Down 5.5% - MarketBeat
Wed, 17 Apr 2024
Passage Bio (PASG) Looks Good: Stock Adds 5.4% in Session - Yahoo Movies UK
Tue, 19 Mar 2024
What is the Market's View on Passage Bio Inc (PASG) Stock's Price and Volume Trends Tuesday? - InvestorsObserver
Thu, 07 Mar 2024
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know - Yahoo Finance
Tue, 05 Mar 2024
Should You Buy Passage Bio Inc (PASG) Stock After it Has Risen 2.56% in a Week? - InvestorsObserver
Tue, 05 Mar 2024
Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program - BioBuzz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 55.7 (%) |
| Shares Short | 1,320 (K) |
| Shares Short P.Month | 558 (K) |
| EPS | -1.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.7 % |
| Return on Equity (ttm) | -65.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -0.65 |
| PEG Ratio | 0 |
| Price to Book value | 0.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|